article thumbnail

Cedars-Sinai Cardiologist Leads the American Society of Transplantation

DAIC

Jon Kobashigawa, MD, of the Smidt Heart Institute at Cedars-Sinai, is an expert in heart transplantation, heart failure, and other complex cardiac conditions. Kobashigawa will also represent the American Society of Transplantation in discussions with government agencies and policymakers about organ transplant legislation. “Dr.

article thumbnail

Revolutionary Genomic Study Sheds Light on Immune Microenvironment in Transplanted Pediatric Hearts

DAIC

© THE TEXAS HEART INSTITUTE 2024 milla1cf Tue, 02/13/2024 - 17:56 February 13, 2024 — Pediatric heart transplantation has long been hailed as a life-saving intervention for children suffering from end-stage heart failure. The research is a collaborative effort between leading medical institutions.

article thumbnail

Artificially transplanted mitochondria in endothelial cells promote mitophagy

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 21 May 2024; doi:10.1038/s41569-024-01041-x A study in Nature describes a single-cell-type strategy for vascular cell therapies that involves the artificial transplantation of mitochondria to endothelial cells, which promotes mitophagy and facilitates the formation of functional vessels in ischaemic tissue (..)

article thumbnail

Machine Perfusion Could Help Address Transplant Crisis for Pediatric Liver Diseases

HCPLive

New data from the UNOS database presented at NASPGHAN 2024 details characteristics and outcomes of pediatric liver transplant patients receiving machine perfused organs.

article thumbnail

Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study

DAIC

In organ transplantation, an extended criteria donor is defined as having perceived risk factors linked to poor subsequent outcomes, for example, those with age >55 or ischemic times exceeding 4 hours, which sometimes leads to rejection of the donor organ. utilizing the Paragonix SherpaPak CTS (p=0.022).

article thumbnail

Abstract 4144084: Enhanced External Counterpulsation as a Novel Treatment for Heart Transplant Candidates with Ischemic Heart Failure with Reduced Ejection Fraction

Circulation

Circulation, Volume 150, Issue Suppl_1 , Page A4144084-A4144084, November 12, 2024. Despite being a heart transplantation candidate, she declined revascularization and sought alternative treatments for angina, dyspnea, and daily activity limitations. The patient underwent EECP, consisting of 35 one-hour sessions over seven weeks.

article thumbnail

Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

DAIC

By the end of the study cardiologists performed 10% fewer biopsies in the first year post-transplant and 40% fewer in the second year post-transplant despite an increase in follow-up biopsy rates for dual positives. Hanna , CareDx President and CEO.